Saluda Medical (ASX:SLD) wins FDA approval for its CAP24 surgical paddle lead, opening access to 30% of the US spinal cord stimulation market.
30
Stocks in Spotlight
View all →-
Financials · Growth Stocks Powerhouse Ventures (ASX:PVL) US$50m Partner Commitment Puts CIO Fund Re-Rate in Focus June 26, 2026 -
Growth Stocks WiseTech Global (ASX:WTC) Why the A$30 Sell-Off Could Be a Long-Term Opportunity June 23, 2026 -
